Wednesday, February 26, 2014
Question of the Day February 26, 2014 Is anyone seeing any signs that PCCA, IACP, and others who predicted that compounding pharmacies would close their doors is becoming a reality? In my opinion the exact reverse has happened--it is a expanding and rapidly growing area? How can Congress expect the FDA to even begin to keep up with the way it is now exploding? What are states doing to keep up? What can they do to keep up?
Compounding Sales Representative Opening in Abilene Texas
Medical Sales Representative
My Pharmacy - Abilene, TX
My Pharmacy - Abilene, TX
| My Pharmacy and Compounding Lab Regional Sales Representative SA110 General Purpose Promote compounding pharmaceutical product sales through effective interaction with health care professionals and organizations to increase the awareness and use of the company's pharmaceutical products in a specified territory. Main Job Tasks and Responsibilities
Bachelor’s degree from an accredited College or State University 2+ years in outside medical sales with hospitals and clinics Ability to travel within a set region Proven leadership and decision-making ability Must have a consistent track record of accomplishments and success in sales MS Word, Excel, PowerPoint Benefits: Medical Dental Vision Indeed - 30+ days ago - save job - block
» Apply Now
Please review all application instructions before applying.
|
The Pharmacy Compounding Business Continues to Grow--Another Regional Sales Representative Opening
Regional Sales Representative for Compounded Pharmaceuticals - new Pharmacy Compounding Connection - Washington, DC - +1 location
ATTENTION EXPERIENCED PHARMACEUTICAL AND MEDICAL SALES PROFESSIONALS. Pharmacy Compounding Connection, (PCC) is seeking exceptionally talented Sales...
|
IACP touts being first pharmacy association to issue nominations for FDA's Request for Bulk Drug Substances for both 503A and 503B
Attention IACP Members: Your Academy is the first pharmacy association to issue nominations for FDA's Request for Bulk Drug Substances - for Both 503A & 503B Facilities. An IACP member alert is distributing now
http://bit.ly/1hh8qfb . Please note that you will need to log into the Members only site to view the comprehensive list of IACP documents submitted to the FDA.
Pharmacy Technician II- Sterile Compounding Job Opening
Wednesday, February 26, 2014
Pharmacy Technician II-
Pharmagen Laboratories is hiring Pharmacy Technician II- Sterile Compounding on
Wed, 26 Feb 2014 17:03:25 GMT. Compounding Pharmacists in our state-of-the-art
USP 797 sterile room. SUMMARY Responsible for sterile compounding under the
supervision of a pharmacist, to...
more information found here
Compounding Pharmacy Business Manager (Bellevue) Job Opening
Compounding Pharmacy Business Manager (Bellevue)
Paramount Pharmacy is looking for an outstanding full-time (100% FTE) Compounding Pharmacy Business Manager with pharmacy billing experience to join our Pharmacy team. This position requires Pharmacy Technician licensure and is responsible for assisting Paramount Pharmacy by performing non-professional/technical tasks related to delivery of pharmaceutical services.
These functions may include:
•Verification of Benefits with Patients prior to filling prescription
•Customer Service
•Pharmacy Billing (finalizing submission)
• Revenue Cycle Management
•Adheres to Paramount Pharmacy Services policies and procedures
• Performs related duties as required
•The successful candidate will build and manage a customer service team of pharmacy technicians
Paramount Pharmacy offers a comfortable work environment, excellent benefits, a competitive salary. This position provides opportunities to work in a fast-paced, challenging, diverse and rewarding environment.
Requirements:
•Compound Pharmacy Billing experience as a Pharmacy Technician or equivalent education/experience.
•Must pass background check and drug test
Legal Requirement:
•Pharmacy Technician licensure with State of Washington (Dept. of Health)
•Desired: More than 1 year of Compound Pharmacy Technician experience or significant customer service experience preferred.
compensation: DOE, benefit package avialable after 60 days
These functions may include:
•Verification of Benefits with Patients prior to filling prescription
•Customer Service
•Pharmacy Billing (finalizing submission)
• Revenue Cycle Management
•Adheres to Paramount Pharmacy Services policies and procedures
• Performs related duties as required
•The successful candidate will build and manage a customer service team of pharmacy technicians
Paramount Pharmacy offers a comfortable work environment, excellent benefits, a competitive salary. This position provides opportunities to work in a fast-paced, challenging, diverse and rewarding environment.
Requirements:
•Compound Pharmacy Billing experience as a Pharmacy Technician or equivalent education/experience.
•Must pass background check and drug test
Legal Requirement:
•Pharmacy Technician licensure with State of Washington (Dept. of Health)
•Desired: More than 1 year of Compound Pharmacy Technician experience or significant customer service experience preferred.
- Principals only. Recruiters, please don't contact this job poster.
- do NOT contact us with unsolicited services or offers
- quoted from here
Company that makes drugs for Ohio executions says it opposes lethal injection
CLEVELAND, Ohio -- The drug maker that manufactured the two drugs used for Ohio executions says it opposes lethal injection and makes products to save lives, not end them.
How the drugs got to Ohio underscores how far states will go to obtain drugs for executions.
Hospira Inc. of Lake Forest, Ill., made the midazolam and hydromorphone that Ohio received in late 2013 for its lethal injections, a state spokesman said. The two types of drugs were used in Dennis McGuire's execution Jan. 16.
read more here
How the drugs got to Ohio underscores how far states will go to obtain drugs for executions.
Hospira Inc. of Lake Forest, Ill., made the midazolam and hydromorphone that Ohio received in late 2013 for its lethal injections, a state spokesman said. The two types of drugs were used in Dennis McGuire's execution Jan. 16.
read more here
NEWS: Mesa Pharmacy prescription orders for February exceed $6.5 million. Sales continue to increase inline with expectations
The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary have continued to increase inline with expectations and have generated gross revenues, excluding allowances for returns and discounts, exceeding $6.5 Million Dollars......
IRVINE, CA, Feb. 26, 2014 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary have continued to increase inline with expectations and have generated gross revenues, excluding allowances for returns and discounts, exceeding $6.5 Million Dollars. "We are currently filling prescriptions for transdermal topical pain medications of approximately $400,000 dollars per day". Stated Andrew Do, Mesa's President and Registered Pharmacist.
As controlled narcotic medications become more problematic and laws continue to limit options for physicians to control pain, other alternatives are being considered. Mesa's non-narcotic trans-dermal formulations for pain management are becoming more popular for managing pain suffered by injured workers. Mesa is continuing its plan to increase staff for the surge in orders that has occurred as a result of its recent agreement with Trestles Pain Specialists LLC.
About The PAWS Pet Company, Inc.
The PAWS Pet Company, Inc. is undergoing a transition from the pet space to the pharmaceutical space. This exciting transition strategy has been developed to take advantage of the changes underway in traditional medical services. PAWS believes that great opportunities exist in pharmaceuticals and how they are delivered to the public.
About Mesa Pharmacy, Inc.
Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa compounds a series of topical prescription medications, in different strengths, that provide the pain relief doctors seek and that have a very low propensity for addiction. As a result, physicians and insurers need not worry about treating an injured worker and winding up having to treat that worker's potential addiction to pain killing narcotics.
For more information on The PAWS Pet Company go to: www.thepawspetcompany.com
Forward-Looking Statements
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements that are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995).
The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.
SOURCE The PAWS Pet Company, Inc. 
Michael Taylor executed by Missouri using compounded pentobarbital
State fends off legal challenges and goes ahead with lethal injection using unofficial version of drug from unnamed source
Missouri has gone ahead with executing a death-row prisoner using a drug from an unspecified source. The lethal injection of pentobarbital used to kill Michael Taylor, 47, who raped and murdered a teenage girl in 1989, was presumed to have been bought by the state from a compounding pharmacy – a supply arrangement that sparked legal challenges over the potential cruelty of using an unregulated drug.
Taylor offered no final statement. He mouthed silent words to his parents, two clergymen and two other relatives who witnessed his death. As the process began he took two deep breaths before closing his eyes for the last time.continue to read here
Pharmacist Sentenced to Seven Years in Prison for Obtaining $1.7 Million from Health Insurers for Drug He Never Dispensed
| U.S. Attorney’s Office February 25, 2014 |
CHICAGO—A Chicago pharmacist was sentenced to seven years in federal prison after being convicted at trial of collecting more than $1.7 million through false claims he submitted to insurance companies for a drug that he never dispensed and stealing the identities of unsuspecting pharmacy customers to make that money, which he used to finance a lavish lifestyle. The defendant, Ronald Kielar, also created fake documents to make his false insurance claims appear legitimate.
Kielar, 76, of Mundelein, was a pharmacist at the former Cartagena Pharmacy, located in the 1500 block of West Devon Avenue, which was owned by his ex-wife. He was sentenced to five years in prison on six counts of health care fraud and one count of obstruction of justice and received a mandatory consecutive sentence of two years on three counts of aggravated identity theft. Kielar, who was convicted on all 10 counts he was charged with at a trial last fall, was ordered to begin serving the 84-month sentence on June 10.
U.S. District Judge Robert M. Dow, Jr., who imposed the sentence on Friday, also ordered Kielar to pay more than $1.725 million in restitution and to forfeit nearly $78,000 in proceeds from the sale of property he owned in Florida.
According to court documents, Kielar used patients’ insurance information, including their names and dates of birth, to bill for the drug Procrit, which stimulates the production of red blood cells. These patients, however, were never prescribed Procrit, Kielar never provided them with the medication, and the patients never authorized the use of their insurance information to submit claims for payment. After he was indicted, Kielar forged prescriptions, patient receipts, and false invoices to make the insurance claims look legitimate. Between November 2004 and August 2010, Kielar submitted 603 false claims and received more than $1.7 million from Blue Cross and Blue Shield of Illinois and the United Food and Commercial Workers Unions and Employers Midwest Health Benefit Fund.
“Each time [Kielar] hit the submit button on the pharmacy’s computer for a Procrit claim, he made a calculated choice: to lie to the victim insurance company who received, processed, and paid on the claim,” Assistant U.S. Attorney Heather McShain wrote in a sentencing memo. Kielar also betrayed a physician who had been his friend for 40 years and whose name and DEA registration number Kielar used without permission, as well as unsuspecting patients whose personal information he used.
Evidence showed that Kielar used proceeds from the fraud scheme to pay salaries to himself and his ex-wife and then used those funds to pay mortgages on his home in Illinois, as well as properties in Florida and Arizona.
The sentence was announced today by Zachary T. Fardon, United States Attorney for the Northern District of Illinois; Robert J. Holley, Special Agent in Charge of the Chicago Office of the Federal Bureau of Investigation; James Vanderberg, Special Agent in Charge of the U.S. Department of Labor Office of Inspector General in Chicago; and John Redmond, Special Agent in Charge of the Chicago Office of the U.S. Food and Drug Administration Office of Criminal Investigations.
The government was represented by Assistant U.S. Attorneys Heather McShain and Steven J. Dollear.
Kielar, 76, of Mundelein, was a pharmacist at the former Cartagena Pharmacy, located in the 1500 block of West Devon Avenue, which was owned by his ex-wife. He was sentenced to five years in prison on six counts of health care fraud and one count of obstruction of justice and received a mandatory consecutive sentence of two years on three counts of aggravated identity theft. Kielar, who was convicted on all 10 counts he was charged with at a trial last fall, was ordered to begin serving the 84-month sentence on June 10.
U.S. District Judge Robert M. Dow, Jr., who imposed the sentence on Friday, also ordered Kielar to pay more than $1.725 million in restitution and to forfeit nearly $78,000 in proceeds from the sale of property he owned in Florida.
According to court documents, Kielar used patients’ insurance information, including their names and dates of birth, to bill for the drug Procrit, which stimulates the production of red blood cells. These patients, however, were never prescribed Procrit, Kielar never provided them with the medication, and the patients never authorized the use of their insurance information to submit claims for payment. After he was indicted, Kielar forged prescriptions, patient receipts, and false invoices to make the insurance claims look legitimate. Between November 2004 and August 2010, Kielar submitted 603 false claims and received more than $1.7 million from Blue Cross and Blue Shield of Illinois and the United Food and Commercial Workers Unions and Employers Midwest Health Benefit Fund.
“Each time [Kielar] hit the submit button on the pharmacy’s computer for a Procrit claim, he made a calculated choice: to lie to the victim insurance company who received, processed, and paid on the claim,” Assistant U.S. Attorney Heather McShain wrote in a sentencing memo. Kielar also betrayed a physician who had been his friend for 40 years and whose name and DEA registration number Kielar used without permission, as well as unsuspecting patients whose personal information he used.
Evidence showed that Kielar used proceeds from the fraud scheme to pay salaries to himself and his ex-wife and then used those funds to pay mortgages on his home in Illinois, as well as properties in Florida and Arizona.
The sentence was announced today by Zachary T. Fardon, United States Attorney for the Northern District of Illinois; Robert J. Holley, Special Agent in Charge of the Chicago Office of the Federal Bureau of Investigation; James Vanderberg, Special Agent in Charge of the U.S. Department of Labor Office of Inspector General in Chicago; and John Redmond, Special Agent in Charge of the Chicago Office of the U.S. Food and Drug Administration Office of Criminal Investigations.
The government was represented by Assistant U.S. Attorneys Heather McShain and Steven J. Dollear.
Around Iowa: Pharmacist's health care fraud trial starts--Allegations are that Michael Stein billed Wellmark for expensive drugs when his pharmacy actually did little work and only acted as a pass through entity for Florida compaines
IOWA CITY
A trial is starting for an Iowa pharmacist accused of fraudulently billing an insurance company for life-saving drugs sent to hemophilia patients.Michael Stein, the owner of Pharmacy Matters in Iowa City, has pleaded not guilty to 15 counts of health care fraud. Jury selection began Monday in federal court in Des Moines.
Prosecutors contend Stein billed Wellmark for expensive drugs to treat hemophilia, when his pharmacy actually did little work in dispensing those drugs. They say his pharmacy acted as a “pass-through entity” for Florida companies, giving them access to the Blue Cross and Blue Shield network.
Stein’s attorneys say the case is a contract dispute between a pharmacist and an insurer.
quoted from here
Feds make Medicare fraud a top priority
By Elaine Silvestrini | Tribune Staff
Published: February 23, 2014 | Updated: February 23, 2014 at 08:51 AM
Published: February 23, 2014 | Updated: February 23, 2014 at 08:51 AM
TAMPA — Four men set up four bogus medical clinics in Tampa.
They pay Medicare clients who allow the clinics to bill Medicare HMO insurance providers in their names for vein procedures they never undergo. Each clinic submits a separate bill for each patient, submitting multiple claims for the same procedures on the same individuals at the same time.
The scam went on for more than three years. Collectively, the men were able to steal more than $2.5 million from federal taxpayers.
continue to read here
They pay Medicare clients who allow the clinics to bill Medicare HMO insurance providers in their names for vein procedures they never undergo. Each clinic submits a separate bill for each patient, submitting multiple claims for the same procedures on the same individuals at the same time.
The scam went on for more than three years. Collectively, the men were able to steal more than $2.5 million from federal taxpayers.
continue to read here
Tuesday, February 25, 2014
Tennessee gets new rules on compounding pharmacies February 25, 2014
More than six months after they were first approved, new rules governing the operation of compounding pharmacies in Tennessee have passed legal muster and gone into effect.
The rules, issued by the state Board of Pharmacy, were drawn up in reaction to a nationwide outbreak of fungal meningitis that hit particularly hard in Tennessee. Sixteen Tennessee patients died after being injected with fungus-tainted spinal steroids shipped from a Massachusetts drug compounding firm.
Reginald Dillard, executive director of the pharmacy board, said the final version of the rules won approval from the state attorney general and went into effect late last month
continue to read here
The rules, issued by the state Board of Pharmacy, were drawn up in reaction to a nationwide outbreak of fungal meningitis that hit particularly hard in Tennessee. Sixteen Tennessee patients died after being injected with fungus-tainted spinal steroids shipped from a Massachusetts drug compounding firm.
Reginald Dillard, executive director of the pharmacy board, said the final version of the rules won approval from the state attorney general and went into effect late last month
continue to read here
Hamburg says FDA's focus on India reflects its place in the global supply chain
She says the FDA is not picking on the country with the actions it has taken
Read more: Hamburg says FDA's focus on India reflects its place in the global supply chain - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/hamburg-says-fdas-focus-india-reflects-its-place-global-supply-chain/2014-02-24#ixzz2uOPJ5DbQ
Subscribe at FiercePharma Manufacturing
Ranbaxy halts production at 2 plants to tackle its regulatory mess
Indian drugmaker says a new board committee is now involved in oversight
Read more: Ranbaxy halts production at 2 plants to tackle its regulatory mess - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/ranbaxy-halts-production-2-plants-tackle-its-regulatory-mess/2014-02-25#ixzz2uOOfx7pE
Subscribe at FiercePharma Manufacturing
The FDA catches another Indian drugmaker falsifying data
Warning letter says USV faked sample weights
Read more: The FDA catches another Indian drugmaker falsifying data - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/fda-catches-another-indian-drugmaker-falsifying-data/2014-02-25#ixzz2uOOJbc3r
Subscribe at FiercePharma Manufacturing
Georgia Supreme Court considers death penalty pain
Should Georgia prison officials tell death row inmates where they bought the drugs that will be used to kill them?
Right now, those officials don't have to reveal their drug supplier -- not to inmates, not to lawyers, not to journalists or activists or anyone else filing a public records request. But the Georgia Supreme Court is considering the question after hearing arguments last week about the potential execution of Warren Lee Hill.
continue to read here
Right now, those officials don't have to reveal their drug supplier -- not to inmates, not to lawyers, not to journalists or activists or anyone else filing a public records request. But the Georgia Supreme Court is considering the question after hearing arguments last week about the potential execution of Warren Lee Hill.
continue to read here
Monday, February 24, 2014
Texas Veterinary Medical Associaton Annual conference February 28-March 2, 2014
ANNUAL CONFERENCE
Saddle up, partner, for the 2014 TVMA Annual ConferenceFebruary 28 – March 2 • College Station
PRE-REGISTRATION IS NOW CLOSED.
If you would like to attend the conference on site registration begins Thursday February 27th at 10:00 a.m. at the Hilton Hotel in College Station.
Look for details in the Texas Veterinarian.
Although the TVMA conference room block deadline is not until Thursday, February 6, we have been informed our conference hotels, the Hilton and the Homestead Suites in College Station, are completely sold out of rooms for Friday, February 28, and Saturday, March 1.
Due to an SEC Indoor Track and Field Meet, TAMU basketball games and the A&M Softball Invitational against UConn, most hotels in the area are sold out. If you plan to attend the TVMA Annual Conference and have NOT secured a hotel room, there is only one way to find availability in Bryan/College Station without calling every hotel in town. On the Bryan/College Station Convention and Visitors Bureau website (www.visitaggieland.com), there is a special feature entitled “Book a Room.” When you enter your arrival and departure dates, it searches the entire area for available hotel rooms. This feature is updated daily.
If you have questions, please do not hesitate to contact Ellen Forsythe, CMP, at 512/452-4224 or eforsythe@tvma.org.
CONFERENCE HEADQUARTERS (location of all social events)
Saddle up, partner, for the 2014 TVMA Annual ConferenceFebruary 28 – March 2 • College Station
If you would like to attend the conference on site registration begins Thursday February 27th at 10:00 a.m. at the Hilton Hotel in College Station.
It’s easy to get into the spirit of the Old West when you come from simple and humble roots. The first TVMA Annual Conference was held in Fort Worth in 1903, making it the oldest veterinary meeting in Texas. Our organization strives to carry on Mark Francis' vision of a unified veterinary profession in the very place where he served as the first dean of the College of Veterinary Medicine at Texas A&M University. Join us in College Station, where veterinarians and students gather to make lifelong connections in the birthplace of veterinary medicine in Texas. We’re homegrown and proud.
The 2014 Conference CE program features 84.5 hours of quality CE featuring great talent from one of the top veterinary schools in the country, Texas A&M University, plus other experts from around the U.S. Attendees can receive up to 23 CE credits by attending morning and evening lectures on Thursday, Friday, Saturday and Sunday. Suppliers will be on hand to visit with practitioners about the latest products, services and equipment.
Look for details in the Texas Veterinarian.
HOTEL ROOMS AT A PREMIUM IN COLLEGE STATION
Although the TVMA conference room block deadline is not until Thursday, February 6, we have been informed our conference hotels, the Hilton and the Homestead Suites in College Station, are completely sold out of rooms for Friday, February 28, and Saturday, March 1.Due to an SEC Indoor Track and Field Meet, TAMU basketball games and the A&M Softball Invitational against UConn, most hotels in the area are sold out. If you plan to attend the TVMA Annual Conference and have NOT secured a hotel room, there is only one way to find availability in Bryan/College Station without calling every hotel in town. On the Bryan/College Station Convention and Visitors Bureau website (www.visitaggieland.com), there is a special feature entitled “Book a Room.” When you enter your arrival and departure dates, it searches the entire area for available hotel rooms. This feature is updated daily.
If you have questions, please do not hesitate to contact Ellen Forsythe, CMP, at 512/452-4224 or eforsythe@tvma.org.
CONFERENCE HEADQUARTERS (location of all social events)
California Board of Pharmacy Take Disciplinary Action Against GJPL, Jay Scott Drugs, Michael's Pharmacy, Mimi Pharmacy, and North Highlands Pharmacy
GJPL Inc., dba Saint Johns Medical Plaza Pharmacy, PHY 43536, Administrative Case AC 4362
Santa Monica, CA
Through a disciplinary action of the board, the license is revoked, the revocation is stayed, and the license is placed on probation for five years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 01/31/2014.
View the decision
Jay Scott Drugs, PHY 40912, Administrative Case AC 3482
Burbank, CA
Through a disciplinary action of the board, the license is revoked.
Decision effective 1/27/2014.
View the decision
Michael’s Pharmacy, PHY 47549, Administrative Case AC 3824
Pasadena, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the license is placed on probation for five years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/14/2014.
View the decision
Mimi Pharmacy, PHY 46271, Administrative Case AC 4026
Reseda, CA
Through a disciplinary action of the board the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 01/31/2014.
View the decision
North Highlands Pharmacy, PHY 39917, Administrative Case AC 3428
North Highlands, CA
Through a disciplinary action of the board, the license is voluntarily surrendered.
Decision effective 1/13/2014.
View the decision
Santa Monica, CA
Through a disciplinary action of the board, the license is revoked, the revocation is stayed, and the license is placed on probation for five years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 01/31/2014.
View the decision
Jay Scott Drugs, PHY 40912, Administrative Case AC 3482
Burbank, CA
Through a disciplinary action of the board, the license is revoked.
Decision effective 1/27/2014.
View the decision
Michael’s Pharmacy, PHY 47549, Administrative Case AC 3824
Pasadena, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the license is placed on probation for five years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/14/2014.
View the decision
Mimi Pharmacy, PHY 46271, Administrative Case AC 4026
Reseda, CA
Through a disciplinary action of the board the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 01/31/2014.
View the decision
North Highlands Pharmacy, PHY 39917, Administrative Case AC 3428
North Highlands, CA
Through a disciplinary action of the board, the license is voluntarily surrendered.
Decision effective 1/13/2014.
View the decision
California Board of Pharmacy Action Decision Against Patricia Helgren, PIC at Precision
Helgren, Patricia, RPH 42842, Administrative Case AC 3769
Bakersfield, CA
Through a disciplinary action of the Board, the license is subject to public reproval and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/11/2014.
View the decision
Bakersfield, CA
Through a disciplinary action of the Board, the license is subject to public reproval and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/11/2014.
View the decision
California Board of Pharmacy Revokes Precision Pharmacy's Licenses, then Stays Revocation, placing them on three Years of Probation-View Decision Here
Precision Pharmacy, LSC 99351, Administrative Case AC 3769
Bakersfield, CA
Through a disciplinary action of the Board, the licenses are revoked, the revocation is stayed, and the licensee is placed on probation for three years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/11/2014.
View the decision
Precision Pharmacy, PHY 47310, Administrative Case AC 3769
Bakersfield, CA
Through a disciplinary action of the Board, the licenses are revoked, the revocation is stayed, and the licensee is placed on probation for three years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/11/2014.
View the decision
Bakersfield, CA
Through a disciplinary action of the Board, the licenses are revoked, the revocation is stayed, and the licensee is placed on probation for three years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/11/2014.
View the decision
Precision Pharmacy, PHY 47310, Administrative Case AC 3769
Bakersfield, CA
Through a disciplinary action of the Board, the licenses are revoked, the revocation is stayed, and the licensee is placed on probation for three years and subject to the terms and conditions as indicated in the attached decision.
Decision effective 02/11/2014.
View the decision
Compounding Sales Job Opening claiming to be with pharmacy with the largest volume PCCA member under one roof out of 2500 members
MEDICAL SALES (TERRITORY MANAGER) (Cincinnati, Ohio)
If you have Pharmaceutical or Medical Sales experience with physician relationships and looking to add HIGH RESIDUAL INCOME, with greater earning potential, and more independence, look no further.
Established relationships with providers a plus (Podiatry, Pain Management, Orthopedic, Neurology, Family Practice, Internal Medicine, Dermatology, Rheumatology, Sports Medicine). Territory Managers around the nation are taking home $100,000 to over $500,000.00 per year.
If you are marketing transdermal pain cream therapy, wound care, scar care therapy, dermatology, or other compounds and getting paid only minimal dollars per script or less than 24% commission, and you are not pleased with the service your compounding pharmacy is providing you or your providers patients, then I would like to speak to you. This unique opportunity can be a supplement to your existing sales position, while utilizing your current contacts and relationships you can capitalize on unlimited possibilities. We offer a generous and aggressive commission based plan that is aimed at growing an established sales force to market transdermal creams and other products.
The number of deaths from oral pain medications have tripled over the past 10 years. Compounded transdermal pain creams are a safe and effective way to deliver medications through the skin to the soft tissue of the muscle, relieving pain at the site of injury while foregoing the risk of oral pain medications.
Transdermal pain therapy is a 30 billion dollar industry and growing. It is a non-addictive, non-narcotic, non-sedating alternative for pain therapy for patients of all ages. Take advantage of this exciting opportunity that offers the highest commissions throughout our distribution network.
Scripts adjudicate from $200.00 to $13,000.00 in range, and we pay 20-24% in commissions. No caps on prescription amounts, and commissions are on ALL refills. Real time sales rep portal for full viewing of sales data by sales representative and/or distributor, updated every thirty minutes.
We work with a pharmacy that is the largest volume PCCA member under one roof out of 2500 members, compounding with only the highest quality ingredients.
They provide Innovative Compounded Transdermal Pain Management, Wound Care Formulations as well as formulations for Scars and Stretch marks. These creams offer many advantages such as:
• Rapid Onset of Relief
• Targets to Site of Pain
• Customized Formulations for Patient Needs and Made to Order
• Non-Narcotic
• Non-Addictive
• Non-Sedating
• Minimal Systemic Concentration
• Minimal Drug Interaction Risk
• Customed Formulations
• Odorless
• Private/Commercial insurance accepted
EVERY provider treats patients with some sort of pain and they see them EVERY day. Many of these physicians are surgeons who would have the capability to write 2 prescriptions for patients with one being for pain and another for the scars that the patients may want to try and reduce.
If you are interested please attach a resume to J.Massa@scottiedogspine.com or reply with your contact information for additional information.
compensation: Up to and over $100,00 per year.
Established relationships with providers a plus (Podiatry, Pain Management, Orthopedic, Neurology, Family Practice, Internal Medicine, Dermatology, Rheumatology, Sports Medicine). Territory Managers around the nation are taking home $100,000 to over $500,000.00 per year.
If you are marketing transdermal pain cream therapy, wound care, scar care therapy, dermatology, or other compounds and getting paid only minimal dollars per script or less than 24% commission, and you are not pleased with the service your compounding pharmacy is providing you or your providers patients, then I would like to speak to you. This unique opportunity can be a supplement to your existing sales position, while utilizing your current contacts and relationships you can capitalize on unlimited possibilities. We offer a generous and aggressive commission based plan that is aimed at growing an established sales force to market transdermal creams and other products.
The number of deaths from oral pain medications have tripled over the past 10 years. Compounded transdermal pain creams are a safe and effective way to deliver medications through the skin to the soft tissue of the muscle, relieving pain at the site of injury while foregoing the risk of oral pain medications.
Transdermal pain therapy is a 30 billion dollar industry and growing. It is a non-addictive, non-narcotic, non-sedating alternative for pain therapy for patients of all ages. Take advantage of this exciting opportunity that offers the highest commissions throughout our distribution network.
Scripts adjudicate from $200.00 to $13,000.00 in range, and we pay 20-24% in commissions. No caps on prescription amounts, and commissions are on ALL refills. Real time sales rep portal for full viewing of sales data by sales representative and/or distributor, updated every thirty minutes.
We work with a pharmacy that is the largest volume PCCA member under one roof out of 2500 members, compounding with only the highest quality ingredients.
They provide Innovative Compounded Transdermal Pain Management, Wound Care Formulations as well as formulations for Scars and Stretch marks. These creams offer many advantages such as:
• Rapid Onset of Relief
• Targets to Site of Pain
• Customized Formulations for Patient Needs and Made to Order
• Non-Narcotic
• Non-Addictive
• Non-Sedating
• Minimal Systemic Concentration
• Minimal Drug Interaction Risk
• Customed Formulations
• Odorless
• Private/Commercial insurance accepted
EVERY provider treats patients with some sort of pain and they see them EVERY day. Many of these physicians are surgeons who would have the capability to write 2 prescriptions for patients with one being for pain and another for the scars that the patients may want to try and reduce.
If you are interested please attach a resume to J.Massa@scottiedogspine.com or reply with your contact information for additional information.
- Principals only. Recruiters, please don't contact this job poster.
- do NOT contact us with unsolicited services or offers
- quoted from here
L-citrulline Not First Time Medisca Has Been in Trouble With FDA; In 2012, the company was sentenced in U.S. district court for unlawfully selling human growth hormone drugs from China.
Recalled Supplement L-citrulline May Endanger Kids, FDA Warns
New York-based compounding firm Medisca recently issued a voluntary recall of certain lot numbers of its L-citrulline products and warned consumers to be on alert for potential problems.
Children are primary users of L-citrulline, an amino acid used to treat genetic disorders found primarily in kids. It is also being studied for use in mild to moderate erectile dysfunction in men.
The FDA reported that several recalled lots of the medication actually contained no L-citrulline. Instead of L-citrulline, the lots contained another drug, N- acetyl-leucine, which is prescribed to treat vertigo.
Eight of the recalled lot numbers were sent to hospitals and pharmacies across the country. The FDA did not identify specifically who received the bad lots.
After receiving reports of several adverse events linked to the faulty drug, the FDA recently released a warning.
“Subpotent L-citrulline in patients with certain urea cycle defects can lead to high ammonia levels, which is serious and potentially life-threatening,” the FDA said.
Several Children Already Affected by Faulty Supplements
At least half a dozen children have already reported health problems from taking what they thought was L-citralline.This amino acid clears excess ammonia from the blood. Too much ammonia in the blood can lead to brain damage and in serious cases, even death.
Cynthia LeMons, the executive director of the National Urea Cycle Disorders Foundation told NBC News that one girl sustained a significant loss of her hair, which came out in clumps, and suffered stomach pains because of excessive ammonia in her blood. The girl had to be hospitalized.
Medisca ships L-citrulline in powder form. From that, the drug can be sold as a power or be compounded into tablets, capsules or liquids.
Most at risk from the faulty supplements are children who take them because of rare urea cycle disorders, which effects 2,000 to 2,500 U.S. kids. While other companies also supply the drug, Medisca is the main supplier.
Parents, caregivers and doctors of patients who take L-citrulline are urged to call their healthcare providers immediately if they have concerns about the product.
The FDA is also asking healthcare professionals to be aware of these recalled lots numbers and not administer them to patients. It also instructs them to return all unused products to Medisca.
The FDA and Troubled Compounding Pharmacies
This is not the first time Medisca has had trouble with its products. In 2012, the company was sentenced in U.S. district court for unlawfully selling human growth hormone drugs from China.The compounding firm was ordered to pay a $15,000 fine and lost $1.7 million.
Other compounding companies have also come under fire for putting the public at risk. In 2012, a contaminated steroid distributed by the New England Compounding Center used to treat back pain resulted in almost 1,000 cases of fungal meningitis which resulted in 64 deaths.
This incident prompted the FDA to pass stricter regulations on compounding pharmacies. In January of 2014, these companies began registering with the FDA – including Medisca.
Medisca released a statement saying the faulty L-citrulline products “represent a potential health hazard. These lots should not be used for any pourpose.”
The FDA said that all adverse reactions should be reported to the agency at MedWatch.
Trial begins for Iowa City compounding pharmacist-Micheal Stein Owner of Pharmacy Matters. Stein is accused of fraud
DES MOINES, Iowa (AP) — A trial is starting for an Iowa pharmacist accused of fraudulently billing an insurance company for life-saving drugs sent to hemophilia patients.
Michael Stein, the owner of Pharmacy Matters in Iowa City, has pleaded not guilty to 15 counts of health care fraud. Jury selection began Monday in federal court in Des Moines.
Prosecutors contend Stein billed Wellmark for expensive drugs to treat hemophilia, when his pharmacy actually did little work in dispensing those drugs. They say his pharmacy acted as a "pass-through entity" for Florida companies, giving them access to the Blue Cross and Blue Shield network.
Stein's attorneys say the case is a contract dispute between a pharmacist and an insurer. They say reasonable minds disagree about whether Stein provided a service for which he could bill Wellmark.
quoted from here
Michael Stein, the owner of Pharmacy Matters in Iowa City, has pleaded not guilty to 15 counts of health care fraud. Jury selection began Monday in federal court in Des Moines.
Prosecutors contend Stein billed Wellmark for expensive drugs to treat hemophilia, when his pharmacy actually did little work in dispensing those drugs. They say his pharmacy acted as a "pass-through entity" for Florida companies, giving them access to the Blue Cross and Blue Shield network.
Stein's attorneys say the case is a contract dispute between a pharmacist and an insurer. They say reasonable minds disagree about whether Stein provided a service for which he could bill Wellmark.
quoted from here
Pegasus Laboratories, Inc. has Sued Lowlite Investments Inc (dba Olympia Compounding Pharmacy) for Patent Infringement
U.S. District Court
Middle District of Florida (Orlando)
CIVIL DOCKET FOR CASE #: 6:14-cv-00051-RBD-TBS
Pegasus Laboratories, Inc. v. Lowlite Investments, Inc. Assigned to: Judge Roy B. Dalton, Jr. Referred to: Magistrate Judge Thomas B. Smith Cause: 35:271 Patent Infringement | Date Filed: 01/10/2014 Jury Demand: Plaintiff Nature of Suit: 830 Patent Jurisdiction: Federal Question |
| Plaintiff | ||
| Pegasus Laboratories, Inc. | represented by | Margaret Diane Mathews Akerman Senterfitt, LLP Suite 1700 401 E Jackson St Tampa, FL 33602-5250 813/223-7333 Fax: 813/223-2837 Email: margaret.mathews@akerman.com LEAD ATTORNEY ATTORNEY TO BE NOTICED Robert Cameron Garrison Lathrop & Gage, LLP Suite 2200 2345 Grand Boulevard Kansas City, MO 64108 816/292-2000 Fax: 816/292-2001 Email: cgarrison@lathropgage.com LEAD ATTORNEY PRO HAC VICE ATTORNEY TO BE NOTICED |
V. | ||
| Defendant | ||
| Lowlite Investments, Inc. doing business as Olympia Compounding Pharmacy | ||
| Date Filed | # | Docket Text |
|---|---|---|
| 01/10/2014 | 1 | COMPLAINT against Lowlite Investments, Inc. with Jury Demand (Filing fee $ 400, receipt number ORL30922) filed by Pegasus Laboratories, Inc. (Attachments: # 1 Exhibits A, B & C, # 2 Exhibits D & E, # 3 Civil Cover Sheet)(IGC) (Entered: 01/13/2014) |
| 01/10/2014 | 2 | SUMMONS issued as to Lowlite Investments, Inc. (issued at intake) (IGC) (Entered: 01/13/2014) |
| 01/13/2014 | 3 | PATENT Report sent to Alexandria, VA. (Attachments: # 1 Complaint, # 2 Exhibits A, B & C, # 3 Exhibits D & E, # 4 Civil Cover Sheet) (IGC) (Entered: 01/13/2014) |
| 01/14/2014 | 4 | ORDER that the Clerk of the Court is directed to REASSIGN this case to another District Judge for all further proceedings. Signed by Senior Judge G. Kendall Sharp on 1/14/2014. (DB) (Entered: 01/14/2014) |
| 01/14/2014 | 5 | Case Reassigned to Judge Roy B. Dalton, Jr.. New case number: 6:14-cv-51-Orl-37TBS. Senior Judge G. Kendall Sharp no longer assigned to the case. (IGC) (Entered: 01/14/2014) |
| 01/15/2014 | 6 | RELATED CASE ORDER AND NOTICE of designation under Local Rule 3.05 - track 2. Notice of pendency of other actions due by 1/29/2014. Signed by Deputy Clerk on 1/15/2014. (Attachments: # 1, # 2, # 3 )(VMF) (ctp) (Entered: 01/15/2014) |
| 01/15/2014 | 7 | INTERESTED PERSONS ORDER Certificate of interested persons and corporate disclosure statement due by 1/29/2014. Signed by Judge Roy B. Dalton, Jr. on 1/15/2014. (VMF) (ctp) (Entered: 01/15/2014) |
| 01/17/2014 | 8 | MOTION for R. Cameron Garrison to appear pro hac vice by Pegasus Laboratories, Inc.. (Mathews, Margaret) Motions referred to Magistrate Judge Thomas B. Smith. (Entered: 01/17/2014) |
| 01/17/2014 | 9 | ORDER granting 8 motion for R. Cameron Garrison to appear pro hac vice on behalf of Plaintiff. Signed by Magistrate Judge Thomas B. Smith on 1/17/2014. (Smith, Thomas) (Entered: 01/17/2014) |
| 01/22/2014 | 10 | ***PRO HAC VICE FEES paid and Special Admission Attorney Certification Form filed by attorney R. Cameron Garrison appearing on behalf of Pegasus Laboratories, Inc. (Filing fee $10, receipt number ORL31135) Related document: 8 MOTION for R. Cameron Garrison to appear pro hac vice. (IGC) (Entered: 01/22/2014) |
| 01/29/2014 | 11 | CERTIFICATE of Interested Persons and Corporate Disclosure Statement re: 7 Interested Persons Order by Pegasus Laboratories, Inc. identifying Corporate Parent PBI-Gordon Corporation for Pegasus Laboratories, Inc. (Mathews, Margaret) Modified on 1/30/2014 (LMM). Modified on 1/30/2014 (LMM). (Entered: 01/29/2014) |
| 01/29/2014 | 12 | NOTICE of compliance re 9 Order on motion to appear pro hac vice by Pegasus Laboratories, Inc. (Garrison, Robert) (Entered: 01/29/2014) |
| 01/30/2014 | 13 | Remark: Doc. 11 has been reviewed. Signed by Judge Roy B. Dalton, Jr. on 1/30/2014. (LLM) (Entered: 01/30/2014) |
Pegasus Laboratories voluntarily dismisses federal complaint against Weatherford Compounding Pharmacy
| 01/10/2014 | 10 | ORDER ADMINISTRATIVELY CLOSING CASE: Parties shall file stipulation of dismissal by 2/10/2014. Signed by District Judge Carlos Murguia on 1/10/2014. (mm) (Entered: 01/10/2014) |
| 01/28/2014 | 11 | NOTICE OF VOLUNTARY DISMISSAL by Pegasus Laboratories, Inc. (Garrison, Robert) (Entered: 01/28/2014) |
What's New on the FDA Drugs Site --from FDA 2/21/2014
- Guidance for Industry: E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility (updated)
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- Guidance for Industry: New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products (PDF - 248KB)
- Food and Drug Administration/Xavier University PharmaLink Conference—Leadership in a Global Supply Chain, March 19, 2014 and March 21, 2014, Xavier University, 3800 Victory Pkwy.,Cincinnati, OH 45207. Meeting information
- National Drug Code Directory
- Over-The-Counter Drug Monograph System - Past, Present and Future; Public Hearing, March 25-26, 2014, FDA White Oak Campus, 10903 New Hampshire Avenue, Bldg. 31, Room 1503 (Great Room), Silver Spring, MD. Meeting information
- Safe Use Initiative: Funding and Support (updated)
Oklahoma Horse Racing Commission Minutes from January 2014 Meeting
REPORTS
Chairman Leonard made the following reports:
• The Commission Executive Director, through responsibility delegated to him by
the Commission, reviewed and approved the following CY 2014 renewal licenses
for Independent Testing Laboratories:
• BMM North America, Inc. D/B/A BMM Testlabs
• Gaming Laboratories International, LLC
• Nick Farley and Associates D/B/A Eclipse Compliance Testing
• This year’s Legislative Session will convene on Monday, February 3, 2014.
Commission Staff will start reviewing bills related to the industry after the January
16, 2014 deadline for filing and introducing bills. Commissioner Lucas reported
that two bills had been drafted at the Commission’s request to: (1) expand the
Commission Executive Director’s authority to purchase vehicles and law
enforcement equipment and (2) set a deadline of three years for undisbursed
funds of $50.00 or less in the Horsemen’s Funds at a racetrack to be
redistributed to the Fund for use in the current race meeting.
OKLAHOMA HORSE RACING COMMISSION
REGULARLY SCHEDULED MEETING
JANUARY 16, 2014
MINUTES
CALL TO ORDER/ROLL CALL
Chairman Leonard called the Regularly Scheduled Meeting of the Commission to order
at 9:38 a.m. in Track North at Remington Park Racetrack and Casino, Oklahoma City,
Oklahoma.
Commission members answering roll call were Commissioner Bollenbach,
Commissioner Bowers, Commissioner Burton, Commissioner Goumaz, Commissioner
Harrell, Commissioner Kirk, Commissioner Lucas, Commissioner Sanders and
Chairman Leonard. Mr. Neal Leader, Commission Counsel, was present as well as the
following Commission staff members: Mr. Constantin A. Rieger, Mr. Mike Dixon, Ms.
Mary Ann Roberts, Mr. Mike Corey, Ms. Bonnie Morris and Ms. E J Brees.
Approximately fourteen persons attended and signed the registry which is part of the
record.
APPROVAL OF MINUTES
Commissioner Bowers moved to approve the drafted Minutes from the November 21,
2013 Regularly Scheduled Commission Meeting. Commissioner Goumaz seconded the
motion. The vote was as follows:
Aye: Mr. Bowers, Ms. Goumaz, Mr. Burton, Mr. Harrell, Mr. Lucas,
Mr. Sanders, Mr. Leonard
Abstain: Mr. Bollenbach, Mr. Kirk
PROPOSED AMENDMENTS TO DIRECTIVE ON COMMISSIONSANCTIONED
THRESHOLDS
Background
The Ad Hoc Committee on Medications met on September 17, 2013 and December 16,
2013 to discuss possible amendments to the Directive on Commission-Sanctioned
Subscribe to:
Posts (Atom)